Fecal treatment to clear gut bacteria resistant to antibiotics
Part of Infections clinical trials.
This study tests a stool-based treatment (fecal microbiota treatment) to help remove “carbapenem-resistant” bacteria living in the gut. If you carry these bacteria without being sick, the goal is to reduce or stop that colonization.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- A rectal swab test shows you currently carry carbapenem-resistant Enterobacteriaceae (CRE)
- You can legally give informed consent
- You do not have a new stomach or gut infection other than possible C. difficile
- You do not have certain ongoing gut conditions (like celiac, inflammatory bowel disease, or IBS)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at a treatment made from stool donors (called fecal microbiome therapy) to help remove carbapenem-resistant gut bacteria in the body. It’s mainly for adults who recently tested positive for these bacteria on a rectal swab, and it checks whether the therapy can help eradicate the germs.
This Phase 3 study tests whether a fecal microbiota transplant (FMT) can eliminate hard-to-treat bacteria in the gut, such as ESBL or carbapenem-resistant bacteria. If it works, it may reduce future infections and antibiotic-resistant illness.
This trial tests whether one or multiple fecal transplants from a healthy donor can help treat both a recurring C. diff infection and active ulcerative colitis. It aims to find the best schedule for the procedure.
This study uses fecal microbiota transplantation (FMT) — transferring gut bacteria from a healthy donor — to see how it affects the gut microbiome in people with ulcerative colitis, metabolic syndrome, or recurrent C. difficile infection. It may help stabilize the gut bacteria and improve symptoms.
This early-stage study tests whether a one-time transfer of “donor gut bacteria” can improve ulcerative colitis. It’s designed for people with mild to moderate ulcerative colitis who are stable on maintenance treatment.
This trial studies whether fecal microbiota transplantation (a procedure that transfers healthy stool bacteria) can change a person’s gut bacteria after repeated C. difficile infection. It may help reduce recurring infections by restoring a healthier balance of gut microbes.
Hear when a new Enterobacteriaceae Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.